CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
2.560
-0.150 (-5.54%)
At close: Aug 20, 2026, 4:00 PM EDT
2.540
-0.020 (-0.78%)
After-hours: Aug 20, 2026, 6:43 PM EDT
CervoMed Revenue
CervoMed had revenue of $331.30K in the twelve months ending June 30, 2026, down -95.74% year-over-year. In the year 2025, CervoMed had annual revenue of $4.01M, down -58.86%.
Revenue (ttm)
$331.30K
Revenue Growth
-95.74%
P/S Ratio
117.74
Revenue / Employee
$22,086
Employees
15
Market Cap
38.70M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.01M | -5.73M | -58.86% |
| Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
| Dec 31, 2023 | 7.14M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 71.67K | -302.88K | -80.87% |
| Dec 31, 2012 | 374.54K | -195.93K | -34.35% |
| Dec 31, 2011 | 570.48K | 530.29K | 1,319.48% |
| Dec 31, 2010 | 40.19K | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 40.19K | -268.57K | -86.98% |
| Dec 31, 2007 | 308.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.62M |
| Aligos Therapeutics | 31.52M |
| Veru Inc. | 16.89M |
| Radiopharm Theranostics | 10.86M |
| Seres Therapeutics | 1.88M |
| Nutriband | 1.80M |
| Hyperion DeFi | 1.40M |
| Serina Therapeutics | 130.00K |
CRVO News
- 12 hours ago - CervoMed price target lowered to $7 from $9 at Roth Capital - TheFly
- 9 days ago - CervoMed Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 10 days ago - CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 10 days ago - CervoMed price target lowered to $18 from $27 at Canaccord - TheFly
- 13 days ago - CervoMed Quarterly report: Q2 2026 - Filings
- 13 days ago - CervoMed Earnings release: Q2 2026 - Filings
- 15 days ago - CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - GlobeNewsWire
- 16 days ago - CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) - GlobeNewsWire